Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Regurgitation is a clinical term for the backward flow of fluid, most often describing either: Cardiac regurgitation, where a heart valve (mitral, aortic, tricuspid, or pulmonary) fails to close properly, resulting in blood leaking backward and potentially causing heart failure over time; or Gastrointestinal regurgitation, which is the movement of stomach contents up the esophagus and sometimes into the mouth, classically seen in gastroesophageal reflux disease (GERD), and can also happen physiologically in infants. Regurgitation is a sign or process, not a discrete molecular entity or therapeutic target. "Regurgitation" should not be used as a molecular target entry; for pharmacological or biological target annotation, the specific valve protein or receptor (e.g., "Mitral valve," "Aortic valve," or the physiological regulators of sphincters) should be referenced, not the generic process of regurgitation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Regurgitation.